The NF-κB pathway is associated with poor prognosis and response to drug treatment, and represents an emerging drug target in CLL.17,40–44 The mechanism underlying high UGT2B17 expression in B-cells remains to be fully explored. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.